1-deoxynojirimycin has been researched along with glucagon-like peptide 1 in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (19.05) | 29.6817 |
| 2010's | 17 (80.95) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horowitz, M; Lee, A; Morley, JE; Patrick, P; Wishart, J | 1 |
| Arakawa, M; Ebato, C; Fujitani, Y; Hirose, T; Kawamori, R; Mita, T; Shimizu, T; Watada, H | 1 |
| Fujita, H; Hosoba, M; Katsuura, Y; Morii, T; Narita, T; Sato, T; Yamada, Y | 1 |
| Babu, RK; Deshpande, MC; Trivedi, RK; Venkateswarlu, V | 1 |
| Hosoba, M; Kakei, M; Nanjo, H; Narita, T; Sato, T; Satoh, K; Uchinami, H; Yamada, Y; Yamamoto, Y | 1 |
| Aoki, K; Masuda, K; Miyazaki, T; Terauchi, Y; Togashi, Y | 1 |
| Aoki, K; Miyazaki, T; Nagakura, J; Orime, K; Terauchi, Y; Togashi, Y | 1 |
| Deshpande, MC; Gadewar, ST; Mantri, AH; Venkateswarlu, V | 1 |
| Aoyama, T; Fujiwara, H; Hattori, A; Iwasa, M; Kawamura, I; Kobayashi, H; Minatoguchi, S; Nishigaki, K; Shiraki, T; Sumi, S; Takemura, G; Ushikoshi, H; Yamada, Y; Yamaki, T; Yasuda, S | 1 |
| Hamaguchi, T; Katsuno, T; Konishi, K; Kusunoki, Y; Miuchi, M; Miyagawa, J; Murai, K; Nagai, E; Namba, M; Ochi, F; Tokuda, M | 1 |
| Aoki, K; Kamiyama, H; Masuda, K; Shibuya, M; Terauchi, Y; Yoshimura, K | 1 |
| Fujita, H; Hosoba, M; Morii, T; Narita, T; Sato, T; Tsukiyama, K; Yamada, Y; Yamashita, R; Yokoyama, H | 1 |
| Kishimoto, M; Noda, M | 1 |
| Kaku, H; Tajiri, Y; Yamada, K | 1 |
| Anzai, N; Jomori, T; Jutabha, P; Kaneko, S; Lee, EY; Miki, T; Seino, S; Zhang, X | 1 |
| Aoki, K; Shibata, E; Taguri, M; Tajima, K; Terauchi, Y | 1 |
| Goto, M; Hariya, N; Mochizuki, K; Osonoi, T; Saito, M | 1 |
| Kishida, Y; Ohno, H; Oki, K; Okubo, H; Yoneda, M | 1 |
| Fujimoto, K; Furusawa, K; Jomori, T; Kimura, I; Lee, EY; Miki, T; Miyamoto, J; Taknaka, T; Uematsu, S; Zhang, X | 1 |
| Iwasa, M; Kanamori, H; Kawaguchi, T; Kawasaki, M; Mikami, A; Minatoguchi, S; Naruse, G; Nishigaki, K; Yamada, Y; Yoshida, A | 1 |
| Aerts, JMFG; Boot, R; Foppen, E; Herrera Moro Chao, D; Jansen, K; Kalsbeek, A; Kooijman, S; Marques, AR; Mergen, C; Mirzaian, M; Ottenhoff, R; Overkleeft, H; Parlevliet, ET; Rensen, PCN; Scheij, S; Seeley, RJ; Tschöp, MH; van Eijk, M; van Roomen, C; Verhoek, M; Wang, D; Wang, Y; Yi, CX | 1 |
10 trial(s) available for 1-deoxynojirimycin and glucagon-like peptide 1
| Article | Year |
|---|---|
The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
Topics: 1-Deoxynojirimycin; Adult; Aged; Appetite; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Middle Aged; Obesity; Peptide Fragments; Postprandial Period; Protein Precursors | 2002 |
Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects.
Topics: 1-Deoxynojirimycin; Acarbose; Adult; Blood Glucose; Cross-Over Studies; Enzyme Inhibitors; Female; Glucagon-Like Peptide 1; Humans; Insulin; Intercellular Adhesion Molecule-1; Interleukin-6; Lipids; Lipoprotein Lipase; Male; Middle Aged; Obesity; Postprandial Period; Single-Blind Method; Vascular Cell Adhesion Molecule-1; Viscera | 2008 |
Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men.
Topics: 1-Deoxynojirimycin; Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Food; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incretins; Insulin; Kinetics; Male; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide levels in healthy men.
Topics: 1-Deoxynojirimycin; Adult; Blood Glucose; Cross-Over Studies; Enzyme Inhibitors; Fasting; Food; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Kinetics; Male | 2010 |
Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Adult; Aged; Deoxyglucose; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Enzyme Inhibitors; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Male; Middle Aged; Serum Albumin; Weight Loss; Young Adult | 2011 |
Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Topics: 1-Deoxynojirimycin; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Food-Drug Interactions; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients.
Topics: 1-Deoxynojirimycin; Asian People; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Inositol; Male; Middle Aged; Obesity; Postprandial Period | 2012 |
Anorexigenic effects of miglitol in concert with the alterations of gut hormone secretion and gastric emptying in healthy subjects.
Topics: 1-Deoxynojirimycin; Adult; Appetite; Appetite Depressants; Female; Gastric Emptying; Ghrelin; Glucagon-Like Peptide 1; Humans; Male; Obesity; Peptide YY; Young Adult | 2012 |
Comparison of efficacy and safety of taking miglitol dissolved in water during a meal and taking a miglitol tablet just before a meal in patients with type 2 diabetes.
Topics: 1-Deoxynojirimycin; Blood Glucose; Breakfast; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Postprandial Period; Tablets | 2016 |
Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Leptin; Male; Metformin; Middle Aged; Pyrimidines; Treatment Outcome | 2016 |
11 other study(ies) available for 1-deoxynojirimycin and glucagon-like peptide 1
| Article | Year |
|---|---|
Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients.
Topics: 1-Deoxynojirimycin; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dietary Fats; Dietary Proteins; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Postprandial Period | 2009 |
Design and evaluation of oral bioadhesive controlled release formulations of miglitol, intended for prolonged inhibition of intestinal alpha-glucosidases and enhancement of plasma glucagon like peptide-1 levels.
Topics: 1-Deoxynojirimycin; Administration, Oral; Animals; Blood Glucose; Chemistry, Pharmaceutical; Delayed-Action Preparations; Dogs; Drug Evaluation, Preclinical; Enzyme Inhibitors; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Hyperglycemia; Hypoglycemic Agents; Intestine, Small; Male; Random Allocation; Rats; Rats, Sprague-Dawley | 2009 |
A case of insulinoma following total gastrectomy--effects of an alpha-glucosidase inhibitor on suppressing GIP and GLP-1 elevations.
Topics: 1-Deoxynojirimycin; Female; Gastrectomy; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Insulinoma; Middle Aged; Pancreatic Neoplasms; Postprandial Period | 2010 |
Targeting enteral endocrinal L-cells with dietary carbohydrates, by increasing the availability of miglitol in the intestinal lumen, leads to multi-fold enhancement of plasma glucagon-like peptide-1 levels in non-diabetic canines.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Animals; Biological Availability; Blood Glucose; Cellulose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dogs; Drug Implants; Enteroendocrine Cells; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Intestine, Small; Male; Methylcellulose; Polymers; Postprandial Period; Rats; Rats, Sprague-Dawley | 2011 |
Both stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemia-reperfusion injury in rabbits.
Topics: 1-Deoxynojirimycin; Administration, Oral; Animals; Blood Glucose; Blood Pressure; Drug Synergism; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycogenolysis; Heart; Heart Rate; Hypoglycemic Agents; Insulin; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Peptide Fragments; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rabbits; Receptors, Glucagon | 2011 |
A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
Topics: 1-Deoxynojirimycin; Aged; Biomarkers; Blood Glucose; Case-Control Studies; Deoxyglucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Male; Middle Aged; Monitoring, Physiologic; Pilot Projects; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Distinct action of the α-glucosidase inhibitor miglitol on SGLT3, enteroendocrine cells, and GLP1 secretion.
Topics: 1-Deoxynojirimycin; Acarbose; Animals; Enteroendocrine Cells; Glucagon-Like Peptide 1; Glucose Transporter Type 2; Glycoside Hydrolase Inhibitors; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Sodium-Glucose Transport Proteins; Sodium-Glucose Transporter 1; Xenopus laevis | 2015 |
Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model.
Topics: 1-Deoxynojirimycin; Animals; Diet, High-Fat; Disease Models, Animal; Gastrointestinal Microbiome; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease | 2017 |
Gut carbohydrate inhibits GIP secretion via a microbiota/SCFA/FFAR3 pathway.
Topics: 1-Deoxynojirimycin; Animals; Carbohydrate Metabolism; Fatty Acids, Volatile; Gastric Inhibitory Polypeptide; Gastrointestinal Microbiome; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Incretins; KATP Channels; Maltose; Mice; Receptors, G-Protein-Coupled | 2018 |
The intestine responds to heart failure by enhanced mitochondrial fusion through glucagon-like peptide-1 signalling.
Topics: 1-Deoxynojirimycin; Animals; Cells, Cultured; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Dynamins; Enteroendocrine Cells; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycoside Hydrolase Inhibitors; GTP Phosphohydrolases; Heart Failure; Ileum; Incretins; Male; Membrane Proteins; Mitochondria, Heart; Mitochondrial Dynamics; Mitochondrial Proteins; Myocytes, Cardiac; Paracrine Communication; Peptide Fragments; Rats, Inbred Dahl; Rats, Sprague-Dawley; Signal Transduction; Sodium Chloride, Dietary; Ventricular Function, Left | 2019 |
The Iminosugar AMP-DNM Improves Satiety and Activates Brown Adipose Tissue Through GLP1.
Topics: 1-Deoxynojirimycin; Adamantane; Adipose Tissue, Brown; Animals; Brain; Glucagon-Like Peptide 1; Glucose; Male; Mice; Mice, Inbred C57BL; Obesity; Rats; Rats, Wistar; Satiation; Signal Transduction | 2019 |